Transcenta Holding Limited (HKG:6628)

Market Cap	657.46M
Revenue (ttm)	11.98M
Net Income (ttm)	-308.92M
Shares Out	405.84M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,524,910
Average Volume	977,780
Open	1.550
Previous Close	1.490
Day's Range	1.480 - 1.650
52-Week Range	0.500 - 2.220
Beta	0.07
RSI	61.82
Earnings Date	May 29, 2025

About Transcenta Holding

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States. It develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST808, a humanized antibody regulating B/plasma cell; TST005, a PD-L1/TGF-β bi-functio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 184
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6628

Financial Performance

In 2024, Transcenta Holding's revenue was 11.26 million, a decrease of -79.09% compared to the previous year's 53.85 million. Losses were -290.29 million, -37.24% less than in 2023.

Financial numbers in CNY